12.00 USD
+0.08
0.67%
At close Apr 21, 4:00 PM EDT
After hours
12.00
+0.00
0.00%
1 day
0.67%
5 days
-6.18%
1 month
-16.32%
3 months
-23.76%
6 months
-32.43%
Year to date
-30.60%
1 year
-63.19%
5 years
-81.37%
10 years
-61.19%
 

About: Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.

Employees: 504

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

24% more call options, than puts

Call options by funds: $7.05M | Put options by funds: $5.68M

2.2% less ownership

Funds ownership: 83.76% [Q3] → 81.57% (-2.2%) [Q4]

8% less funds holding

Funds holding: 140 [Q3] → 129 (-11) [Q4]

10% less capital invested

Capital invested by funds: $175M [Q3] → $157M (-$18.2M) [Q4]

24% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 46

34% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 29

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$16.50
38%
upside
Avg. target
$16.50
38%
upside
High target
$16.50
38%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
DA Davidson
Linda Bolton Weiser
9% 1-year accuracy
9 / 99 met price target
38%upside
$16.50
Neutral
Maintained
19 Feb 2025

Financial journalist opinion

Based on 3 articles about MED published over the past 30 days

Negative
Zacks Investment Research
7 hours ago
Medifast to Report Q1 Earnings: What Investors Should Expect
MED's first-quarter results may show challenges in customer acquisition amid market headwinds and shifting consumer trends.
Medifast to Report Q1 Earnings: What Investors Should Expect
Positive
Zacks Investment Research
6 days ago
Medifast Trades Near 52-Week Low: What's the Best Move Now?
MED faces steep revenue declines and coach losses but aims to rebound through innovation, marketing and new GLP-1-focused initiatives.
Medifast Trades Near 52-Week Low: What's the Best Move Now?
Negative
Seeking Alpha
3 weeks ago
Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect
Medifast, Inc.'s business is deteriorating as GLP-1 medication has lowered demand, causing a vicious flywheel effect as coaches are exiting the platform. The company is trying to reposition itself as a GLP-1 adjacent business, but the repositioning hasn't shown results so far with a deteriorating immediate earnings outlook. MED stock now trades below the company's net cash position, but due to high earnings uncertainty, the low valuation is justified.
Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect
Neutral
Zacks Investment Research
2 months ago
MED Q4 Earnings Beat, Revenues Dip Y/Y on Lower Customer Acquisition
Medifast's Q2 results show challenges related to weak customer acquisition. However, it is prioritizing efforts to enhance coach productivity in the near term.
MED Q4 Earnings Beat, Revenues Dip Y/Y on Lower Customer Acquisition
Neutral
Seeking Alpha
2 months ago
Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson Operator Greetings and welcome to the Medifast Fourth Quarter 2024 Earnings Conference Call.
Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
Medifast (MED) Q4 Earnings and Revenues Beat Estimates
Medifast (MED) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to earnings of $1.09 per share a year ago.
Medifast (MED) Q4 Earnings and Revenues Beat Estimates
Neutral
Business Wire
2 months ago
Medifast Announces Fourth Quarter and Full Year 2024 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Revenue of $119.0 million, with revenue per active earning coach of $4,391 Independent active earning OPTAVIA coaches of 27,100 Net income of $0.8 million (non-GAAP adjusted net income of $1.1 million) Earnings per diluted share ("EPS") of.
Medifast Announces Fourth Quarter and Full Year 2024 Financial Results
Neutral
Business Wire
2 months ago
Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the fourth quarter and full year ended December 31, 2024 on Tuesday, February 18, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chie.
Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024
Neutral
Zacks Investment Research
2 months ago
MED Focused on GLP-1 Solutions Amid Customer Acquisition Challenges
With a strategic focus on innovation and a robust operational framework, Medifast is well-placed for growth in the weight loss and GLP-1 medication space.
MED Focused on GLP-1 Solutions Amid Customer Acquisition Challenges
Neutral
Zacks Investment Research
3 months ago
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
MED's new OPTAVIA ASCEND product line combines high-protein meals, fiber-rich nutrients and personalized coaching.
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
Charts implemented using Lightweight Charts™